BioAtla, Inc.
BCAB- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826892
No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding BioAtla, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 81 | 97 | +16 |
| Shares | 26.4M | 25.5M | −880.5K (−3.3%) |
| Value | $518.4M | $127.7M | −$390.7M (−75.4%) |
New holders (30)
Institutions that held BioAtla, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
Sold out (14)
Institutions that held BioAtla, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Great Point Partners LLC | 864,300 | $17.0M |
| Perceptive Advisors LLC | 661,200 | $13.0M |
| Woodline Partners LP | 446,141 | $8.76M |
| Sphera Funds Management Ltd. | 180,006 | $3.53M |
| Rafferty Asset Management, LLC | 83,078 | $1.63M |
| Hudson Bay Capital Management LP | 71,400 | $1.40M |
| UBS Group AG | 70,994 | $1.39M |
| Voloridge Investment Management, LLC | 18,973 | $372.0K |
| MetLife Investment Management | 4,977 | $97.7K |
| Metropolitan Life Insurance Co | 3,979 | $78.1K |
| Signaturefd, LLC | 162 | $3.00K |
| State of Wyoming | 44 | $1.00K |
| Northwestern Mutual Wealth Management Co | 8 | $0 |
| Rinkey Investments | 10 | $0 |